Jinping Cai

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Cellular MSI-H score: a robust predictive biomarker for immunotherapy response and survival in gastrointestinal cancer.

Cellular MSI-H score: a robust predictive biomarker for immunotherapy response and survival in gastrointestinal cancer.

Journal: American journal of cancer research

Published: October 02, 2024

Development of a streamlined NGS-based TCGA classification scheme for gastric cancer and its implications for personalized therapy.

Development of a streamlined NGS-based TCGA classification scheme for gastric cancer and its implications for personalized therapy.

Journal: Journal of gastrointestinal oncology

Published: May 11, 2024

Tumor immune microenvironment analysis of non-small cell lung cancer development through multiplex immunofluorescence.

Tumor immune microenvironment analysis of non-small cell lung cancer development through multiplex immunofluorescence.

Journal: Translational lung cancer research

Published: April 29, 2024

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.

Journal: Journal for immunotherapy of cancer

Published: August 08, 2023

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study.

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study.

Journal: JCO precision oncology

Published: March 30, 2023

A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites.

A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites.

Journal: Anti-cancer drugs

Published: February 27, 2023

Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection.

Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection.

Journal: Frontiers in oncology

Published: December 09, 2022

Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma.

Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma.

Journal: Frontiers in immunology

Published: December 05, 2022

Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer.

Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer.

Journal: Journal of translational medicine

Published: October 18, 2022

The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study.

The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study.

Journal: Cancers

Published: September 11, 2022

Identification of BIK as an unfavorable prognostic marker and novel therapeutic target in microsatellite stable colorectal cancer harboring KRAS mutations.

Identification of BIK as an unfavorable prognostic marker and novel therapeutic target in microsatellite stable colorectal cancer harboring KRAS mutations.

Journal: American journal of cancer research

Published: August 03, 2022

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.

Journal: Journal for immunotherapy of cancer

Published: May 19, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026